Showing results (391-400 of 421) with videos related to

Sort By:
Pageof 43
Haematologica|June 26, 2025
Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registriesGuillaume Moulis, Frederick Chen, Giuseppe Carli, et al.
International Journal of Cancer|December 30, 2016
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306)Dominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Ebiomedicine|July 19, 2021
Neuroinflammatory profiles regulated by the redox environment predicted cognitive dysfunction in people living with HIV: A cross-sectional studyRachel K Spooner, Brittany K Taylor, Cassandra M Moshfegh, et al.
Onkologie|September 13, 2007
Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre studySven Bornhak, Else Heidemann, Hans-Joachim Herschlein, et al.
Science (New York, N.Y.)|April 25, 2020
Determination of the melanocortin-4 receptor structure identifies Ca2+ as a cofactor for ligand bindingJing Yu, Luis E Gimenez, Ciria C Hernandez, et al.
Nature|February 11, 2020
Virtual discovery of melatonin receptor ligands to modulate circadian rhythmsReed M Stein, Hye Jin Kang, John D McCorvy, et al.
Autophagy Reports|February 26, 2025
Alterations of PINK1-PRKN signaling in mice during normal agingZahra Baninameh, Jens O Watzlawik, Xu Hou, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Alterations of PINK1-PRKN signaling in mice during normal agingZahra Baninameh, Jens O Watzlawik, Xu Hou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)M Michl, S Stintzing, L Fischer von Weikersthal, et al.
Nature Communications|December 8, 2019
Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptorsAnastasiia Gusach, Aleksandra Luginina, Egor Marin, et al.
Pageof 43